Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company is headquartered in Los Angeles, California.
52W High
$2.10
52W Low
$0.20
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.53
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-7.37
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.54
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
36.71%
Institutions (25–75% balanced)
12.18%
Shares Outstanding
230,929,000
Float
98,311,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.25
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.53%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.0186
Previous
-0.0182
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025